These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38852673)

  • 21. Evaluation of particle size distribution of sub-visible particles in powder injections with different packaging forms - small-sized sub-visible particles should not be ignored.
    Wang T; Lu E; Dai Q; Huang X; Yao Q; Sha X
    Drug Dev Ind Pharm; 2023 Sep; 49(9):551-558. PubMed ID: 37647269
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Comparative profile of the use of filter needles in Quebec and France in healthcare facility].
    Painchart L; Odou P; Bussières JF
    Ann Pharm Fr; 2018 Jan; 76(1):71-77. PubMed ID: 29145996
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Biopharmaceutical Industry Perspective on the Control of Visible Particles in Biotechnology-Derived Injectable Drug Products.
    Mathonet S; Mahler HC; Esswein ST; Mazaheri M; Cash PW; Wuchner K; Kallmeyer G; Das TK; Finkler C; Lennard A
    PDA J Pharm Sci Technol; 2016; 70(4):392-408. PubMed ID: 27091885
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CONTAMINATION OF ANTI-VEGF DRUGS FOR INTRAVITREAL INJECTION: How Do Repackaging and Newly Developed Syringes Affect the Amount of Silicone Oil Droplets and Protein Aggregates?
    Schargus M; Werner BP; Geerling G; Winter G
    Retina; 2018 Oct; 38(10):2088-2095. PubMed ID: 28841584
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Particulate matter in injectable drug products.
    Langille SE
    PDA J Pharm Sci Technol; 2013; 67(3):186-200. PubMed ID: 23752747
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The need for new control strategies for particulate matter in parenterals.
    Poms J; Sacher S; Nixdorf M; Dekner M; Wallner-Mang S; Janssen I; Khinast JG; Schennach R
    Pharm Dev Technol; 2019 Jul; 24(6):739-750. PubMed ID: 30821571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Maximizing patient safety: filter needle use with glass ampules.
    Heiss-Harris GM; Verklan MT
    J Perinat Neonatal Nurs; 2005; 19(1):74-81. PubMed ID: 15796427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Particulate and microbial contamination in in-use admixed parenteral nutrition solutions.
    Oie S; Kamiya A
    Biol Pharm Bull; 2005 Dec; 28(12):2268-70. PubMed ID: 16327163
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glass particle contamination threat in nursing practice: A pilot study.
    Erkoc Hut A; Yazici ZA
    J Adv Nurs; 2021 Jul; 77(7):3189-3191. PubMed ID: 33855755
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of filtration on the presence of particulate and oxycodone content of injections prepared from crushed OxyContin® tablets.
    Patel P; Patel RP; Brandon S; McLean S; Bruno R; de Graaff B
    Curr Drug Saf; 2012 Jul; 7(3):218-24. PubMed ID: 22950988
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Particulate matter determination in LVPs produced in Dutch hospital pharmacies, Part 1: Particle-counting accuracy.
    Van der Veen J; Verbrugge P; Van de Vaart FJ; Boom FA
    PDA J Pharm Sci Technol; 1997; 51(2):81-8. PubMed ID: 9146039
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Particle contamination of parenteralia and in-line filtration of proteinaceous drugs.
    Werner BP; Winter G
    Int J Pharm; 2015 Dec; 496(2):250-67. PubMed ID: 26556624
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Conducting Clinical Risk Assessments for Visible Particulate Matter in Parenteral Preparations.
    Ayres JD
    PDA J Pharm Sci Technol; 2018; 72(6):626-639. PubMed ID: 30158238
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Best Practices to Quantify and Identify Particulate Matter on the Interior Surfaces of Single-Use Systems.
    Wormuth K; Gaston F; Gauthier M; Cantin V; Montenay N
    PDA J Pharm Sci Technol; 2024 Feb; 78(1):90-99. PubMed ID: 37714566
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Usefulness of the final filter of the IV infusion set in intravenous administration of drugs--contamination of injection preparations by insoluble microparticles and its causes.
    Kuramoto K; Shoji T; Nakagawa Y
    Yakugaku Zasshi; 2006 Apr; 126(4):289-95. PubMed ID: 16596019
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Subvisible Particulate Contamination in Cell Therapy Products-Can We Distinguish?
    Vollrath I; Mathaes R; Sediq AS; Jere D; Jörg S; Huwyler J; Mahler HC
    J Pharm Sci; 2020 Jan; 109(1):216-219. PubMed ID: 31521641
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Particulate contamination in New Zealand intravenous solutions.
    Passl WJ; Waring JM
    N Z Med J; 1980 Mar; 91(655):177-9. PubMed ID: 6929987
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stability of doripenem in vitro in representative infusion solutions and infusion bags.
    Psathas PA; Kuzmission A; Ikeda K; Yasuo S
    Clin Ther; 2008 Nov; 30(11):2075-87. PubMed ID: 19108795
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantitation of protein particles in parenteral solutions using micro-flow imaging.
    Huang CT; Sharma D; Oma P; Krishnamurthy R
    J Pharm Sci; 2009 Sep; 98(9):3058-71. PubMed ID: 18937372
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Particles in infusion fluids. Preventive effectiveness of terminal filters. Comparative study].
    Arosio G; Vigasio F; Vegna AM; Lanza G; Corsini M; Rastrelli GF
    Minerva Anestesiol; 1981 Apr; 47(4):155-68. PubMed ID: 7242964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.